A randomized trial comparing misoprostol three and seven days after methotrexate for early abortion

Mitchell D Creinin, Eric Vittinghoff, Stephanie Galbraith, Cynthia Klaisle

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

OBJECTIVE: Our purpose was to determine whether vaginal misoprostol 7 days rather than 3 days after methotrexate injection increases the percent of successful abortions on the day of misoprostol administration. STUDY DESIGN: A randomized controlled trial was performed in women requesting an abortion at ≤56 days' gestation. Eighty-six women were treated with methotrexate 50 mg/m2 intramuscularly followed 3 days (group 1) or 7 days (group 2) later by vaginal misoprostol 800 μg. The misoprostol dose was repeated if the abortion did not occur. RESULTS: Complete abortion occurred in 38 of 46 (83%) patients in group 1 and 39 of 40 (98%) in group 2 (p = 0.033). Of the women with complete abortions, 30 of 46 (65%) in group 1 and 27 of 40 (68%) in group 2 aborted the same day as the first or second dose of misoprostol (p = 0.823). Vaginal bleeding lasted 14 ± 5 (mean ± SD) days in group 1 and 17 ± 9 days in group 2. The remaining women aborted after a delay of 24 ± 6 days in group 1 and 28 ± 13 days in group 2. For these women vaginal bleeding lasted 18 ± 17 and 14 ± 7 days, respectively, and the human chorionic gonadotropin-β level was ≤ 25 IU/L by 22 ± 7 days after the abortion in group 1 and 19 ± 9 days in group 2. Treatment failures in group 1 were four continuing pregnancies (9%), two incomplete abortions (4%), and two women who requested surgical termination after receiving both medications (4%). The treatment failure in group 2 was an incomplete abortion. Methotrexate and misoprostol side effects were infrequent. CONCLUSIONS: Methotrexate and vaginal misoprostol are more effective abortifacients when the misoprostol is given 7 days rather than 3 days after methotrexate. This treatment regimen may offer an alternative to surgical abortion or the use of antiprogestins and prostaglandin for medical abortion.

Original languageEnglish (US)
Pages (from-to)1578-1584
Number of pages7
JournalAmerican Journal of Obstetrics and Gynecology
Volume173
Issue number5
DOIs
StatePublished - 1995

Fingerprint

Misoprostol
Methotrexate
Incomplete Abortion
Uterine Hemorrhage
Treatment Failure
Abortifacient Agents
Pregnancy
Chorionic Gonadotropin
Prostaglandins
Randomized Controlled Trials
Injections

Keywords

  • abortion
  • Methotrexate
  • misoprostol
  • vaginal ultrasonography

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynecology

Cite this

A randomized trial comparing misoprostol three and seven days after methotrexate for early abortion. / Creinin, Mitchell D; Vittinghoff, Eric; Galbraith, Stephanie; Klaisle, Cynthia.

In: American Journal of Obstetrics and Gynecology, Vol. 173, No. 5, 1995, p. 1578-1584.

Research output: Contribution to journalArticle

Creinin, Mitchell D ; Vittinghoff, Eric ; Galbraith, Stephanie ; Klaisle, Cynthia. / A randomized trial comparing misoprostol three and seven days after methotrexate for early abortion. In: American Journal of Obstetrics and Gynecology. 1995 ; Vol. 173, No. 5. pp. 1578-1584.
@article{6ab1c2bc49ef4191beb1576e9dade304,
title = "A randomized trial comparing misoprostol three and seven days after methotrexate for early abortion",
abstract = "OBJECTIVE: Our purpose was to determine whether vaginal misoprostol 7 days rather than 3 days after methotrexate injection increases the percent of successful abortions on the day of misoprostol administration. STUDY DESIGN: A randomized controlled trial was performed in women requesting an abortion at ≤56 days' gestation. Eighty-six women were treated with methotrexate 50 mg/m2 intramuscularly followed 3 days (group 1) or 7 days (group 2) later by vaginal misoprostol 800 μg. The misoprostol dose was repeated if the abortion did not occur. RESULTS: Complete abortion occurred in 38 of 46 (83{\%}) patients in group 1 and 39 of 40 (98{\%}) in group 2 (p = 0.033). Of the women with complete abortions, 30 of 46 (65{\%}) in group 1 and 27 of 40 (68{\%}) in group 2 aborted the same day as the first or second dose of misoprostol (p = 0.823). Vaginal bleeding lasted 14 ± 5 (mean ± SD) days in group 1 and 17 ± 9 days in group 2. The remaining women aborted after a delay of 24 ± 6 days in group 1 and 28 ± 13 days in group 2. For these women vaginal bleeding lasted 18 ± 17 and 14 ± 7 days, respectively, and the human chorionic gonadotropin-β level was ≤ 25 IU/L by 22 ± 7 days after the abortion in group 1 and 19 ± 9 days in group 2. Treatment failures in group 1 were four continuing pregnancies (9{\%}), two incomplete abortions (4{\%}), and two women who requested surgical termination after receiving both medications (4{\%}). The treatment failure in group 2 was an incomplete abortion. Methotrexate and misoprostol side effects were infrequent. CONCLUSIONS: Methotrexate and vaginal misoprostol are more effective abortifacients when the misoprostol is given 7 days rather than 3 days after methotrexate. This treatment regimen may offer an alternative to surgical abortion or the use of antiprogestins and prostaglandin for medical abortion.",
keywords = "abortion, Methotrexate, misoprostol, vaginal ultrasonography",
author = "Creinin, {Mitchell D} and Eric Vittinghoff and Stephanie Galbraith and Cynthia Klaisle",
year = "1995",
doi = "10.1016/0002-9378(95)90652-5",
language = "English (US)",
volume = "173",
pages = "1578--1584",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - A randomized trial comparing misoprostol three and seven days after methotrexate for early abortion

AU - Creinin, Mitchell D

AU - Vittinghoff, Eric

AU - Galbraith, Stephanie

AU - Klaisle, Cynthia

PY - 1995

Y1 - 1995

N2 - OBJECTIVE: Our purpose was to determine whether vaginal misoprostol 7 days rather than 3 days after methotrexate injection increases the percent of successful abortions on the day of misoprostol administration. STUDY DESIGN: A randomized controlled trial was performed in women requesting an abortion at ≤56 days' gestation. Eighty-six women were treated with methotrexate 50 mg/m2 intramuscularly followed 3 days (group 1) or 7 days (group 2) later by vaginal misoprostol 800 μg. The misoprostol dose was repeated if the abortion did not occur. RESULTS: Complete abortion occurred in 38 of 46 (83%) patients in group 1 and 39 of 40 (98%) in group 2 (p = 0.033). Of the women with complete abortions, 30 of 46 (65%) in group 1 and 27 of 40 (68%) in group 2 aborted the same day as the first or second dose of misoprostol (p = 0.823). Vaginal bleeding lasted 14 ± 5 (mean ± SD) days in group 1 and 17 ± 9 days in group 2. The remaining women aborted after a delay of 24 ± 6 days in group 1 and 28 ± 13 days in group 2. For these women vaginal bleeding lasted 18 ± 17 and 14 ± 7 days, respectively, and the human chorionic gonadotropin-β level was ≤ 25 IU/L by 22 ± 7 days after the abortion in group 1 and 19 ± 9 days in group 2. Treatment failures in group 1 were four continuing pregnancies (9%), two incomplete abortions (4%), and two women who requested surgical termination after receiving both medications (4%). The treatment failure in group 2 was an incomplete abortion. Methotrexate and misoprostol side effects were infrequent. CONCLUSIONS: Methotrexate and vaginal misoprostol are more effective abortifacients when the misoprostol is given 7 days rather than 3 days after methotrexate. This treatment regimen may offer an alternative to surgical abortion or the use of antiprogestins and prostaglandin for medical abortion.

AB - OBJECTIVE: Our purpose was to determine whether vaginal misoprostol 7 days rather than 3 days after methotrexate injection increases the percent of successful abortions on the day of misoprostol administration. STUDY DESIGN: A randomized controlled trial was performed in women requesting an abortion at ≤56 days' gestation. Eighty-six women were treated with methotrexate 50 mg/m2 intramuscularly followed 3 days (group 1) or 7 days (group 2) later by vaginal misoprostol 800 μg. The misoprostol dose was repeated if the abortion did not occur. RESULTS: Complete abortion occurred in 38 of 46 (83%) patients in group 1 and 39 of 40 (98%) in group 2 (p = 0.033). Of the women with complete abortions, 30 of 46 (65%) in group 1 and 27 of 40 (68%) in group 2 aborted the same day as the first or second dose of misoprostol (p = 0.823). Vaginal bleeding lasted 14 ± 5 (mean ± SD) days in group 1 and 17 ± 9 days in group 2. The remaining women aborted after a delay of 24 ± 6 days in group 1 and 28 ± 13 days in group 2. For these women vaginal bleeding lasted 18 ± 17 and 14 ± 7 days, respectively, and the human chorionic gonadotropin-β level was ≤ 25 IU/L by 22 ± 7 days after the abortion in group 1 and 19 ± 9 days in group 2. Treatment failures in group 1 were four continuing pregnancies (9%), two incomplete abortions (4%), and two women who requested surgical termination after receiving both medications (4%). The treatment failure in group 2 was an incomplete abortion. Methotrexate and misoprostol side effects were infrequent. CONCLUSIONS: Methotrexate and vaginal misoprostol are more effective abortifacients when the misoprostol is given 7 days rather than 3 days after methotrexate. This treatment regimen may offer an alternative to surgical abortion or the use of antiprogestins and prostaglandin for medical abortion.

KW - abortion

KW - Methotrexate

KW - misoprostol

KW - vaginal ultrasonography

UR - http://www.scopus.com/inward/record.url?scp=0028784690&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028784690&partnerID=8YFLogxK

U2 - 10.1016/0002-9378(95)90652-5

DO - 10.1016/0002-9378(95)90652-5

M3 - Article

C2 - 7503204

AN - SCOPUS:0028784690

VL - 173

SP - 1578

EP - 1584

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 5

ER -